Acute hyperglycemia alters von Willebrand factor but not the fibrinolytic system in elderly subjects with normal or impaired glucose tolerance

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 8, 2004, Pages 629-635

  Coppola, Ludovico ^a,b   Coppola, Antonino ^a   Grassia, Antonio ^a   Mastrolorenzo, Luigia ^a   Lettieri, Biagio ^b   De Lucia, Domenico ^b   De Nanzio, Annarita ^a   Gombos, Giorgio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acute hyperglycemia; Elderly; Fibrinolysis; Von Willebrand factor

Indexed keywords

ASPARTAME; FIBRINOGEN; GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ASPARTAME; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; VON WILLEBRAND FACTOR;

EID: 10044265503     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200412000-00002     Document Type: Article

References (41)

1. Fuller JH, Shipley MJ, Rose G, Jarrett MJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. BMJ 1983; 287:867-870.
2. Kannel WB, McGee DI. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241:2035-2038.
3. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48:937-942.
4. Stamler J, Vaccaro O, Neaton J, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
5. Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. Diabetes Care 1998; 21:360-367.
6. Coutinho M, Gerstein HC, Wang J, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22:233-240.
7. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23:1830-1834.
8. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of the fasting and the 2-hour diagnostic criteria. Arch Intern Med 2001; 161:397-404.
9. Mazza A, Pessina AC, Pavei A, Scarpa R, Tikhonoff V, Caviglia E. Predictors of stroke mortality in elderly people from general population. The Cardiovascular Study in the Elderly. Eur J Epidemiol 2001; 17:1097-1104.
10. Qiao Q, Pyorala K, Pyorala M, Nissinen A, Lindstrom J, Tilvis R, et al. Two-hour glucose is better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002; 23:1267-1275.
11. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340:14-22
12. Davies M, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310:1137-1140.
13. Thompson S, Kienast MJ, Pyke S, Haverkate F, Loo JV. Haemostatic factors and the risk of myocardial infarction or sudden cardiac ischemic death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641.
14. Hamsten A, Erksson P. Fibrinolysis and atherosclerosis. Balliers Clin Haematol 1995; 8:345-359.
15. Wilkerson Wr, Sane DC. Aging and thrombosis. Semin Thromb Hemost 2002; 28:555-568.
16. Morise T, Takeuchi Y, Kawano M, Koni I, Takeda R. Increased plasma levels of immunoreactive endothelin and von Willebrand Factor in NIDDM patients. Diabetes Care 1995; 18:87-89.
17. Juhan-Vague I. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28: 371-380.
18. Juan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34:457-462.
19. Andres R. Aging, diabetes and obesity. Mt Sinai J Med 1981; 48: 489-495.
20. Jackson RA. Mechanisms of age-related glucose intolerance. Diabetes Care 1990; 13:9-19.
21. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998; 21:1236-1239.
22. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24:1485-2001.
23. Leurs PB, van Oerle R, Stolk RP, Grobbee DE, Hamulyak K, Wolffenbuttel BHR. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factor in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 2002; 25: 1340-1345.
24. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-1197.
25. Clauss A. Gerinnungs physiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957; 17:237-246.
26. Pandolfi A, Giaccari A, Cilli C, Alberta MM, Morviducci L, De Filippis EA, et al. Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type1 in the rat. Acta Diabetol 2001; 38:71-76.
27. Gabriely I, Yang XM, Cases JA, Ma XH, Rossetti L, Barzilai N. Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway. Atherosclerosis 2002; 160:115-122.
28. Nordt TH, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13:1822-1828.
29. Ceriello A, Curcio F, dello Russo P, Pegoraro I, Stel G, Amstad P, et al. The defence against free radical protects endothelial cells from hyperglycemia-induced plasminogen activator inhibitor overproduction. Blood Coagul Fibrinolysis 1995; 6:133-137.
30. Zhang J, Ren S, Sun D, Shen GX. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18:1140-1148.
31. Yamamoto K, Takeshita K, Shimokawa T, Yi H, Isobe K, Loskutoff DJ, et al. Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci 2002; 99:890-895.
32. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998; 47:290-293.
33. Schäfer K, Fujisawa K, Konstantinides S, Loskutoff DJ. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15:1840-1842.
34. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes 2002; 51:1131-1137.
35. von Kanel R, Nelesen RA, Le DT, Ziegler MG, Dimsdale JE. Decrease in plasma von Willebrand factor concentration following glucose ingestion: the role of insulin sensitivity. Metabolism 2001; 50:1452-1456.
36. Gresele P, Guglielmini G, De Angelis M, Ciferri S, Ciofetta M, Falcinelli E, et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41:1013-1020.
37. Van Zile J, Kilpatrick M, Laimins M, Sagel J, Colwell J, Virella G. Platelet aggregation and release of ATP after incubation with soluble immune complexes purified from the serum of diabetic patients. Diabetes 1981; 30:575-579.
38. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107;3141-3145.
39. Winocour PD, Lopes-Virella M, Laimins M, Colwell JA. Effect of insulin treatment in streptozocin-induced diabetic rats on in vitro platelet function and plasma von Willebrand factor activity and factor VIII-related antigen. J Lab Clin Med 1985; 106:319-325.
40. Sambataro M, Maioli M, Tonolo G, Stehouwer C, van Hinsbergh V, Piarulli F, et al. Insulin sensitivity correlates with glycogen synthesis rate, but not with von Willebrand factor in type 2 diabetes. Eur J Intern Med 2002; 13:439-442.
41. Becker A, van der Does FE, van Hinsbergh VW, Heine RJ, Bouter LM, Stehouwer CD. Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, von Willebrand factor and (pro)insulin. Neth J Med 2003; 61:129-136.